Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    16226919 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Condition: Leber Congenital Amaurosis
Intervention: Biological: rAAV2-CB-hRPE65
2 Recruiting Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
Condition: Leber Congenital Amaurosis
Intervention: Genetic: rAAV2-hRPE65
3 Recruiting Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Conditions: Leber Congenital Amaurosis (LCA);   Eye Diseases;   Eye Diseases, Hereditary;   Retinal Diseases
Intervention: Genetic: AAV2/5-OPTIRPE65
4 Active, not recruiting Safety Study in Subjects With Leber Congenital Amaurosis
Condition: Leber Congenital Amaurosis
Intervention: Biological: AAV2-hRPE65v2
5 Active, not recruiting Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
Conditions: Amaurosis of Leber;   Retinal Diseases
Intervention: Genetic: rAAV2-CBSB-hRPE65

Study has passed its completion date and status has not been verified in more than two years.